CDK6蛋白表达与多发性髓瘤的疾病进展和治疗耐药性有关
Johannes Steinhart1,2, Peter Möller1, Miriam Kull2
1Department of Pathology Ulm University Hospital Ulm Germany.
HemaSphere
|March 4, 2024
概括
循环素依赖性激酶6 (CDK6) 在多发性骨髓瘤 (MM) 中升高,与疾病进展和药物耐药性有关. 在MM患者中增加CDK6表达与较短的无进展生存相关,特别是在莱纳利多米德治疗后.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤 (MM) 是一种血细胞恶性瘤,治愈率有所改善,但仍然有限.
- 耐药性仍然是MM治疗的一个重大挑战.
- 循环素依赖性激酶6 (CDK6) 涉及各种癌症和MM药物耐药性,但其在疾病阶段和大队列中的作用尚不清楚.
研究的目的:
- 研究CDK6表达与疾病阶段,遗传变化和多发性骨髓瘤患者结局的关联.
- 确定CDK6表达水平是否与疾病进展和对治疗的反应相关,特别是lenalidomide.
主要方法:
- 通过免疫组织化学分析了来自146名患者的203个MM样本中的CDK6表达.
- 与疾病阶段 (MGUS,新诊断的MM,复发的MM,外骨髓瘤) 和治疗史 (利那利多米德暴露) 相关的CDK6水平.
- 评估了CDK6表达对接受基于lenalidomide治疗的患者无进展生存的影响.
主要成果:
- 61.5%的MM标本表示CDK6.5.
- CDK6表达逐渐增加,从意义不明的单克隆性胃病变 (MGUS) 到新诊断的MM和复发的MM.
- 在外骨髓瘤中发现了最高的CDK6水平;表达在莱纳利多米德治疗时显著增加,并且与较短的无进展存活相关.
结论:
- CDK6蛋白表达是侵袭性和耐药性多发性骨髓瘤的标志物.
- 增加的CDK6与疾病进展和较差的结果有关,特别是在用lenalidomide治疗的患者中.
- CDK6代表了克服MM药物耐药性的潜在治疗标.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K


